The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Benchmarking the transcriptomic predictive biomarkers for immunotherapy plus chemotherapy: Results from phase III RATIONALE-309 and ORIENT-11 randomized trials.
 
Kehui Chen
No Relationships to Disclose
 
Anlin Li
No Relationships to Disclose
 
Kangqiao Xiong
No Relationships to Disclose
 
Huaqiang Zhou
No Relationships to Disclose
 
Quankun Zhang
No Relationships to Disclose
 
Yizhi Huang
No Relationships to Disclose
 
Zhengyang Yan
No Relationships to Disclose
 
Kai Wu
No Relationships to Disclose
 
Jianhua Zhan
No Relationships to Disclose
 
Zhixin Yu
No Relationships to Disclose
 
Wenfeng Fang
No Relationships to Disclose
 
Yunpeng Yang
No Relationships to Disclose
 
Shen Zhao
No Relationships to Disclose
 
Shaodong Hong
No Relationships to Disclose
 
Li Zhang
Consulting or Advisory Role - AstraZeneca; Innovent Biologics
Speakers' Bureau - AstraZeneca; BeiGene; HenRui; Innovent Biologics; Roche China
Research Funding - Akeso Biopharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chia Tai Tianqing Pharmaceutical Group (Inst); Junshi Pharmaceuticals (Inst); QiLu Pharmaceutical (Inst)